Outcome of Fund Raising Committee Meeting approving the Letter of Offer for Rights Issue

Date: September 28, 2026 National Stock Exchange of India Limited BSE Limited Exchange Plaza, 5th Floor, Phiroze Jeejeebhoy Towers Plot No. C/1, G Block, Dalal Street, Fort Bandra–Kurla Complex, Mumbai 400 001 Bandra (East), Mumbai - 400 051 Maharashtra, India Symbol: NATCOPHARM Scrip Code: 524816 Dear Sir(s)/Madam(s), Sub: Regulations 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, and Outcome of the Fund-raising Committee meeting held on September 25, 2026 Ref: Earlier intimations on Outcome of the Board meeting(s) held on 9th September, 2026 & 25th September, 2026 We refer to our earlier intimations on the captioned subject and would like to inform that the Fund- Raising Committee of the Board at their meeting held today have approved the Letter of Offer for the Rights issue. In this regard, please find enclosed the Letter of Offer dated September 28, 2026 for the Rights issue of the Company which is also being submitted to the SEBI in compliance with Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 (“SEBI ICDR Regulations”). Further we would also like to inform that the Company has obtained ISIN: INE987B20018 for credit of the Rights Entitlements in the demat account of the eligible equity shareholders as on the Record Date in accordance with the provisions of Regulation 77A of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 read with relevant circulars issued by SEBI from time to time in this regard. In this regard, please find enclosed LOF dated September 28, 2026, for the Rights Issue of the Company which is also being submitted with SEBI in compliance with SEBI ICDR Regulations, as amended, and SEBI Circular bearing ref. no. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2025/31 dated March 11, 2025. The meeting of the Committee commenced at 8.15 p.m. and completed at 8.45 p.m. We request you to take the aforesaid on record. Thanking you, Yours faithfully, For Natco Pharma Limited Ch. Venkat Ramesh Company Secretary & Compliance Officer Letter of Offer Dated September 28, 2026 For Eligible Equity Shareholders only Please scan this QR Code to view this Letter of Offer NATCO PHARMA LIMITED Our Company was incorporated as a private limited company under the name “Natco Fine Pharmaceuticals Private Limited” under the Companies Act, 1956 and was granted a certificate of incorporation dated September 19, 1981 by the Registrar of Companies, Andhra Pradesh at Hyderabad. Our Company became a deemed public company with effect from July 1, 1992, pursuant to our intimation to the Registrar of Companies, Andhra Pradesh at Hyderabad by letter dated May 29, 1992, and the word “Private” was deleted from the name of our Company. Subsequently, the name of our Company was changed to “NATCO Pharma Limited” and a fresh certificate of incorporation consequent upon change of name was issued by the Registrar of Companies, Andhra Pradesh at Hyderabad on February 18, 1993. Subsequently, our Company was converted into a public limited company and a fresh certificate of incorporation consequent upon conversion dated December 30, 1994, was issued by the Registrar of Companies, Andhra Pradesh at Hyderabad. For further details, see “General Information” on page 47. Registered and Corporate Office: ‘NATCO House’, Road No. 2, Banjara Hills, Hyderabad - 500034, Telangana, India Tel: +91 40 2354 7532; Contact Person: Chekuri Venkat Ramesh, Company Secretary and Compliance Officer E-mail: investors@natcopharma.co.in; Website: www.natcopharma.co.in Corporate Identity Number: L24230TG1981PLC003201 PROMOTERS OF OUR COMPANY: VENKAIAH CHOWDARY NANNAPANENI, DURGA DEVI NANNAPANENI, RAJEEV NANNAPANENI, NEELIMA SITA NANNAPANENI, VENKAIAH CHOWDARY NANNAPANENI HUF, VISTRA ITCL INDIA LIMITED A/C NEELIMA NANNAPANENI TRUST, VISTRA ITCL INDIA LIMITED A/C DURGADEVI FAMILY TRUST, VISTRA ITCL INDIA LIMITED A/C VCN FAMILY TRUST AND SAU FAMILY TRUST FOR PRIVATE CIRCULATION TO ELIGIBLE EQUITY SHAREHOLDERS OF NATCO PHARMA LIMITED (THE “COMPANY” OR THE “ISSUER”) ONLY ISSUE OF UP TO 17,058,082* FULLY PAID-UP EQUITY SHARES OF FACE VALUE OF ₹2 EACH OF OUR COMPANY (THE “RIGHTS EQUITY SHARES”) FOR CASH AT A PRICE OF ₹750 PER RIGHTS EQUITY SHARE (INCLUDING A PREMIUM OF ₹748 PER RIGHTS EQUITY SHARE) (“ISSUE PRICE”) AGGREGATING UP TO ₹12,794 MILLION* ON A RIGHTS BASIS TO THE ELIGIBLE EQUITY SHAREHOLDERS OF OUR COMPANY IN THE RATIO OF 2 RIGHTS EQUITY SHARES FOR EVERY 21 FULLY PAID-UP EQUITY SHARES HELD BY THE ELIGIBLE EQUITY SHAREHOLDERS ON THE RECORD DATE, THAT IS ON OCTOBER 1, 2026 (“RECORD DATE”) (THE “ISSUE”). FOR FURTHER DETAILS, SEE “TERMS OF THE ISSUE” BEGINNING ON PAGE 83. *Assuming full subscription in the Issue. Subject to finalisation of Basis of Allotment. GENERAL RISKS Investment in equity and equity related securities involve a degree of risk and investors should not invest any funds in the Issue unless they can afford to take the risk with such investment. Investors are advised to read the risk factors carefully before taking an investment decision in this Issue. For taking an investment decision, investors shall rely on their own examination of the issuer and the offer, including the risks involved. The securities being offered in the Issue have not been recommended or approved by the Securities and Exchange Board of India (“SEBI”) nor does SEBI guarantee the accuracy or adequacy of this Letter of Offer. Specific attention of investors is invited to the section “Risk Factors” beginning on page 14. CONFIRMATION Neither our Company nor our Promoters or any of our Directors have been or are identified as Wilful Defaulters or Fraudulent Borrowers. COMPANY’S ABSOLUTE RESPONSIBILITY Our Company, having made all reasonable inquiries, accepts responsibility for and confirms that this Letter of Offer contains all information with regard to our Company and the Issue, which is material in the context of the Issue, and that the information contained in this Letter of Offer is true and correct in all material aspects and is not misleading in any material respect, that the opinions and intentions expressed herein are honestly held and that there are no other facts, the omission of which makes this Letter of Offer as a whole or any such information or the expression of any such opinions or intentions misleading in any material respect. LISTING The existing Equity Shares of our Company are listed on BSE Limited (“BSE”) and National Stock Exchange of India Limited (“NSE” and together with BSE, the “Stock Exchanges”). Our Company has received “in-principle” approvals from NSE and BSE for listing the Rights Equity Shares through their letters each dated September 21, 2026. Our Company will also make applications to NSE and BSE to obtain trading approvals for the Rights Entitlements as required under the SEBI ICDR Master Circular. For the purposes of the Issue, the Designated Stock Exchange is NSE. REGISTRAR TO THE ISSUE KFin Technologies Limited Address: Selenium Tower-B, Plot No. 31 & 32 Gachibowli Financial District, Nanakramguda, Serilingampally Hyderabad - 500 032, Telangana, India. Tel: +91 40 6716 2222/ 1800 309 4001 E-mail: natcopharma.rights@kfintech.com Investor Grievance ID: einward.ris@kfintech.com Contact Person: Williams R Website: www.kfintech.com SEBI Registration No.: INR000000221 ISSUE PROGRAMME LAST DATE FOR CREDIT OF RIGHTS ENTITLEMENTS October 6, 2026 ISSUE OPENING DATE October 12, 2026 LAST DATE FOR ON MARKET RENUNCIATION OF RIGHTS ENTITLEMENTS # October 16, 2026 ISSUE CLOSING DATE* October 22, 2026 FINALISATION OF BASIS OF ALLOTMENT (ON OR ABOUT) October 23, 2026 DATE OF ALLOTMENT (ON OR ABOUT) October 23, 2026 DATE OF CREDIT OF RIGHTS EQUITY SHARES (ON OR ABOUT) October 26, 2026 DATE OF LISTING (ON OR ABOUT) October 27, 2026 #E ligible Equity Shareholders are requested to ensure that renunciation through off-market transfer [Showing first 8,000 characters — download PDF for full document]